PURPOSE: This study was designed to test the ability of the Bcl-2 family inhibitor ABT-263 to potentiate commonly used chemotherapeutic agents and regimens in hematologic tumor models. METHODS: Models of B-cell lymphoma and multiple myeloma were tested in vitro and in vivo with ABT-263 in combination with standard chemotherapeutic regimens, including VAP, CHOP and R-CHOP, as well as single cytotoxic agents including etoposide, rituximab, bortezomib and cyclophosphamide. Alterations in Bcl-2 family member expression patterns were analyzed to define mechanisms of potentiation. RESULTS: ABT-263 was additive with etoposide, vincristine and VAP in vitro in the diffuse large B-cell lymphoma line (DLBCL) DoHH-2, while rituximab potentiated its activity in SuDHL-4. Bortezomib strongly synergized with ABT-263 in the mantle cell lymphoma line Granta 519. Treatment of DoHH-2 with etoposide was associated with an increase in Puma expression, while bortezomib upregulated Noxa expression in Granta 519. Combination of ABT-263 with cytotoxic agents demonstrated superior tumor growth inhibition and delay in multiple models versus cytotoxic therapy alone, along with significant improvements in tumor response rates. CONCLUSIONS: Inhibition of the Bcl-2 family of proteins by ABT-263 enhances the cytotoxicity of multiple chemotherapeutics in hematologic tumors and represents a promising addition to the therapeutic arsenal for treatment of these diseases.
PURPOSE: This study was designed to test the ability of the Bcl-2 family inhibitor ABT-263 to potentiate commonly used chemotherapeutic agents and regimens in hematologic tumor models. METHODS: Models of B-cell lymphoma and multiple myeloma were tested in vitro and in vivo with ABT-263 in combination with standard chemotherapeutic regimens, including VAP, CHOP and R-CHOP, as well as single cytotoxic agents including etoposide, rituximab, bortezomib and cyclophosphamide. Alterations in Bcl-2 family member expression patterns were analyzed to define mechanisms of potentiation. RESULTS:ABT-263 was additive with etoposide, vincristine and VAP in vitro in the diffuse large B-cell lymphoma line (DLBCL) DoHH-2, while rituximab potentiated its activity in SuDHL-4. Bortezomib strongly synergized with ABT-263 in the mantle cell lymphoma line Granta 519. Treatment of DoHH-2 with etoposide was associated with an increase in Puma expression, while bortezomib upregulated Noxa expression in Granta 519. Combination of ABT-263 with cytotoxic agents demonstrated superior tumor growth inhibition and delay in multiple models versus cytotoxic therapy alone, along with significant improvements in tumor response rates. CONCLUSIONS: Inhibition of the Bcl-2 family of proteins by ABT-263 enhances the cytotoxicity of multiple chemotherapeutics in hematologic tumors and represents a promising addition to the therapeutic arsenal for treatment of these diseases.
Authors: S Ackler; M J Mitten; J Chen; J Clarin; K Foster; S Jin; D C Phillips; S Schlessinger; B Wang; J D Leverson; E R Boghaert Journal: Br J Pharmacol Date: 2012-10 Impact factor: 8.739
Authors: Jason J Zoeller; Aleksandr Vagodny; Krishan Taneja; Benjamin Y Tan; Neil O'Brien; Dennis J Slamon; Deepak Sampath; Joel D Leverson; Roderick T Bronson; Deborah A Dillon; Joan S Brugge Journal: Mol Cancer Ther Date: 2019-04-08 Impact factor: 6.261
Authors: Sarah E Alford; Anisha Kothari; Floris C Loeff; Joshua M Eichhorn; Nandini Sakurikar; Henriette M Goselink; Robert L Saylors; Inge Jedema; J H Frederik Falkenburg; Timothy C Chambers Journal: Cancer Res Date: 2015-02-03 Impact factor: 12.701
Authors: Carolyn A Kitchens; Peter R McDonald; Tong Ying Shun; Ian F Pollack; John S Lazo Journal: J Pharmacol Exp Ther Date: 2011-08-31 Impact factor: 4.030
Authors: Kristen E Olberding; Xiaoli Wang; Yanglong Zhu; Jianmin Pan; Shesh N Rai; Chi Li Journal: Cancer Biol Ther Date: 2010-11-01 Impact factor: 4.742